Skip to main content

Share story

Robotics

Faraday Future first FF EAI robotics product completes U.S. regulatory certification

Faraday Future Intelligent Electric Inc. said its first FF EAI robotics product has completed U.S. regulatory certification. The company said the product is about to officially enter sales. Regulatory approvals for the remaining products in the initial batch are advancing and are expected to be finalized soon. This progress brings the company closer to realizing its launch is sale, sale is delivery model. The goal is to start product deliveries within the same month as the launch. The robotics strategy focuses on creating real-world use cases and user value, directly addressing the industry's current lack of true must-have demand. By integrating Web3 and blockchain technologies, the company aims to lead the industry into a new phase of commercialization driven by authentic user needs and value creation. Its goal is to become the first U.S. company to deliver humanoid robot products with positive contribution margins and to rapidly scale deliveries to enter the ranks of leading EAI robotics companies in the U.S.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from GlobeNewswire and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.